Citadel Advisors
GTBP icon

Citadel Advisors’s GT Biopharma GTBP Stock Holding History

Citadel Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33
Closed -$550 – 14690
2023
Q1 		$550 Buy
+33
New +$756 ﹤0.01% 14470
2022
Q2 		– Sell
-517
Closed -$45K – 13338
2022
Q1 		$45K Sell
517
-76
-13% -$6.7K ﹤0.01% 12862
2021
Q4 		$54K Sell
593
-164
-22% -$24.5K ﹤0.01% 13207
2021
Q3 		$153K Buy
+757
New +$228K ﹤0.01% 12357

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's GTBP Position: Q1 2026 in Review

Citadel Advisors reduced its GT Biopharma (GTBP) stake by 18% in Q1 2026, selling an estimated $7.96K and leaving 66,165 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #12604.

Citadel Advisors first reported a position in GTBP in Q2 2021 and has held it in 11 quarters since. The position peaked at $7.91M in Q2 2021. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Citadel Advisors held 66,165 shares of GT Biopharma worth $27K as of Q1 2026.
  • Citadel Advisors sold 14,596 GT Biopharma shares in Q1 2026, an estimated $7.96K.
  • GT Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12604 holding.
  • Citadel Advisors first reported a position in GT Biopharma in Q2 2021 and has held it in 11 quarters since.
  • Citadel Advisors's GT Biopharma position peaked at $7.91M in Q2 2021.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.